Overview
This randomized controlled trial assessed the efficacy of combining oxymetazoline, a topical decongestant, with fluticasone furoate, an intranasal corticosteroid, in treating allergic rhinitis. Participants were assigned to receive either the combination therapy, fluticasone furoate alone, oxymetazoline alone, or a placebo over a four-week period.he primary outcome measured was the total nasal symptom score (TNSS), with secondary outcomes including nasal volume assessed by acoustic rhinometry. Patients were treated once nightly for 4 weeks, with follow-up 2 weeks after treatment to assess symptom relief and safety.
The Takeaways
- The combination therapy (oxymetazoline + fluticasone furoate) significantly reduced total nasal symptom scores (median score: 143) compared to placebo (262) and oxymetazoline alone (219), indicating superior relief.
- Acoustic rhinometry showed that the combination group had a significantly higher nasal volume at the end of treatment than both placebo and oxymetazoline alone—indicating improved nasal airflow and reduced congestion.
- No evidence of rhinitis medicamentosa (rebound congestion) was observed, even with regular use of oxymetazoline for 4 weeks.
- Quality of life scores were similar across groups, and no significant adverse effects were reported.
Why It Matters
Only a portion of patients respond optimally to intranasal steroids alone, leaving a significant portion with persistent symptoms. This study demonstrates that adding oxymetazoline enhances the efficacy of fluticasone furoate, improving objective airflow measures and symptom control without increasing risk. It supports the use of combination therapy as a next-level solution for allergic rhinitis management.
The Link to Allermi
Allermi’s customized formulations include micro-dosed oxymetazoline—the lowest effective therapeutic amount—combined with intranasal corticosteroid. This study validates Allermi’s approach: using controlled, low-dose oxymetazoline to amplify the effects of intranasal corticosteroid, without triggering rebound congestion. Allermi’s data-backed formulations are designed to optimize airflow and comfort while prioritizing long-term safety.
For more details, refer to the full study: "Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of allergic rhinitis: A randomized controlled trial.
